JP2018502600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502600A5 JP2018502600A5 JP2017552233A JP2017552233A JP2018502600A5 JP 2018502600 A5 JP2018502600 A5 JP 2018502600A5 JP 2017552233 A JP2017552233 A JP 2017552233A JP 2017552233 A JP2017552233 A JP 2017552233A JP 2018502600 A5 JP2018502600 A5 JP 2018502600A5
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- plasmid
- seq
- amino acid
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 40
- 239000013612 plasmid Substances 0.000 claims 22
- 235000014655 lactic acid Nutrition 0.000 claims 20
- 239000004310 lactic acid Substances 0.000 claims 20
- 241000894006 Bacteria Species 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 206010052428 Wound Diseases 0.000 claims 5
- 208000027418 Wounds and injury Diseases 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 101000889048 Homo sapiens C-X-C motif chemokine 17 Proteins 0.000 claims 3
- 241001529936 Murinae Species 0.000 claims 3
- 101100167135 Mus musculus Chil3 gene Proteins 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 102100039435 C-X-C motif chemokine 17 Human genes 0.000 claims 2
- 108700009548 Lactobacillus sakacin P Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- VMETVXNVLXCEFC-UHFFFAOYSA-N Sakacin P Chemical compound NC(=O)C(=O)C(C)NC(=O)OC(C)(C)C VMETVXNVLXCEFC-UHFFFAOYSA-N 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 241000186604 Lactobacillus reuteri Species 0.000 claims 1
- 108010053775 Nisin Proteins 0.000 claims 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims 1
- ACQJWVPNGVNRCD-UHFFFAOYSA-N Sakacin A Chemical compound CC(C)(C)N(C)C(=O)NC(C)NC(=O)C(N)CC(O)=O ACQJWVPNGVNRCD-UHFFFAOYSA-N 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 102000055279 human CXCL17 Human genes 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 229940001882 lactobacillus reuteri Drugs 0.000 claims 1
- 239000004309 nisin Substances 0.000 claims 1
- 235000010297 nisin Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 108010027327 sakacin A Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451658-7 | 2014-12-23 | ||
| SE1451658 | 2014-12-23 | ||
| PCT/EP2015/081146 WO2016102660A1 (en) | 2014-12-23 | 2015-12-23 | Methods for wound healing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019156412A Division JP7033109B2 (ja) | 2014-12-23 | 2019-08-29 | 創傷治癒の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502600A JP2018502600A (ja) | 2018-02-01 |
| JP2018502600A5 true JP2018502600A5 (enExample) | 2018-03-22 |
| JP6581208B2 JP6581208B2 (ja) | 2019-09-25 |
Family
ID=55080095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552233A Active JP6581208B2 (ja) | 2014-12-23 | 2015-12-23 | 創傷治癒の方法 |
| JP2019156412A Active JP7033109B2 (ja) | 2014-12-23 | 2019-08-29 | 創傷治癒の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019156412A Active JP7033109B2 (ja) | 2014-12-23 | 2019-08-29 | 創傷治癒の方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10696974B2 (enExample) |
| EP (2) | EP3735979B1 (enExample) |
| JP (2) | JP6581208B2 (enExample) |
| KR (2) | KR102297619B1 (enExample) |
| CN (2) | CN107208107B (enExample) |
| AU (2) | AU2015370982B2 (enExample) |
| CA (1) | CA2971520C (enExample) |
| ES (2) | ES3048233T3 (enExample) |
| WO (1) | WO2016102660A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3408378B1 (en) | 2016-01-25 | 2022-01-12 | NantCell, Inc. | Nk cells with altered cxcl12/cxcr4 signaling |
| BR112019007812A2 (pt) * | 2016-10-31 | 2019-07-16 | Kimberly Clark Co | métodos para arquivar e de recriar um microbioma. |
| CN110157733A (zh) * | 2018-02-11 | 2019-08-23 | 四川大学 | 重组mIL-22BP载体、脂质体复合物及其制备方法和用途 |
| CN117487686A (zh) * | 2018-07-24 | 2024-02-02 | 生命大地女神有限公司 | 选择和使用褪黑素支持细菌以减少婴儿绞痛 |
| MX2020014222A (es) * | 2018-07-24 | 2021-03-09 | Biogaia Ab | Metodos terapeuticos que utilizan cepas bacterianas las cuales son capaces de aumentar los niveles de adenosina. |
| CN109112155A (zh) * | 2018-08-02 | 2019-01-01 | 南昌大学 | 乳酸乳球菌mg1363的构建及其在治疗细菌性阴道炎中的应用 |
| CN109517772A (zh) * | 2018-10-30 | 2019-03-26 | 南昌大学 | 一种乳酸乳球菌mg1363的构建及其在治疗产妇乳头皲裂中的应用 |
| CN109234298A (zh) * | 2018-10-30 | 2019-01-18 | 南昌大学 | 一种卷曲乳杆菌atcc55221的构建及其在治疗产妇乳头皲裂中的应用 |
| JP7045671B2 (ja) * | 2018-11-12 | 2022-04-01 | 有限会社バイオ研 | 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材 |
| US20230310522A1 (en) * | 2019-06-24 | 2023-10-05 | Mendes S.R.L. | Composition with antibacterial and re-epithelializing action including probiotics |
| CN110623792B (zh) * | 2019-09-23 | 2022-05-06 | 温州医科大学附属第一医院 | 一种医学敷料及其制备方法 |
| CN114470007B (zh) * | 2020-11-13 | 2024-10-18 | 葡萄王生技股份有限公司 | 含乳酸菌发酵产物之皮肤创伤外用组合物及其用途 |
| CA3228922A1 (en) | 2021-10-11 | 2023-04-20 | Ajinomoto Co., Inc. | Bacterium modified to express heterologous tat protein |
| WO2023118327A1 (en) | 2021-12-22 | 2023-06-29 | Ilya Pharma Ab | Live bacteria as excipients for proteins |
| AU2022429649A1 (en) * | 2021-12-29 | 2024-08-08 | Ilya Pharma Ab | Treatment of therapy-induced enteropathy |
| KR102752056B1 (ko) * | 2023-07-12 | 2025-01-13 | 전남대학교 산학협력단 | 락토바실러스 루터리(Lactobacillus reuteri) NCHBL-005 균주를 포함하는 창상 예방 또는 치료, 피부 재생 촉진용 조성물 |
| GB202405882D0 (en) | 2024-04-26 | 2024-06-12 | Ilya Pharma Ab | Treatment of mdr infections |
| CN118948906B (zh) * | 2024-10-16 | 2025-02-14 | 温州医科大学附属第一医院 | 一种促进创面愈合的乳酸杆菌生物膜衍生物及其制备方法和应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9521568D0 (en) * | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
| WO1998035035A1 (fr) * | 1997-02-07 | 1998-08-13 | Shionogi & Co., Ltd. | Nouveau recepteur de chimiokine cxc murin |
| AU781679B2 (en) | 1999-07-05 | 2005-06-09 | Intrexon Actobiotics Nv | Delivery of trefoil peptides |
| CA2311201A1 (en) | 1999-08-05 | 2001-02-05 | Genset S.A. | Ests and encoded human proteins |
| US7780961B2 (en) | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
| WO2006124013A2 (en) * | 2004-04-30 | 2006-11-23 | Five Prime Therapeutics, Inc. | Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use |
| WO2006018446A2 (en) | 2004-08-20 | 2006-02-23 | Actogenix Nv | Method to improve lactococcus preservation |
| ES2626610T3 (es) | 2005-08-30 | 2017-07-25 | Intrexon Actobiotics Nv | Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal |
| US20080254014A1 (en) | 2005-10-03 | 2008-10-16 | Actogenix N V | Use of Recombinant Yeast Strain Producing an Anti-Inflammatory Compound to Treat Colitis |
| ES2405552T3 (es) | 2005-11-29 | 2013-05-31 | Actogenix N.V. | Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos |
| US8682619B2 (en) * | 2005-12-14 | 2014-03-25 | The Invention Science Fund I, Llc | Device including altered microorganisms, and methods and systems of use |
| US20110183348A1 (en) | 2010-01-22 | 2011-07-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Compositions and methods for therapeutic delivery with microorganisms |
| RU2008147398A (ru) | 2006-05-02 | 2010-06-10 | Актогеникс Н.В. (Be) | Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов |
| CA2672229A1 (en) | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
| CA2673409A1 (en) | 2006-12-19 | 2009-06-26 | Ferrosan A/S | Wound or tissue dressing comprising lactic acid bacteria |
| RU2009127718A (ru) | 2006-12-19 | 2011-01-27 | Ферросан А/С (Dk) | Раневой или тканевой перевязочный материал, содержащий молочнокислые бактерии |
| EP3124614B1 (en) | 2007-01-12 | 2022-06-08 | Intrexon Actobiotics NV | Lactococcus promoters and uses thereof |
| EP2774621B1 (en) | 2007-01-25 | 2018-01-24 | Intrexon Actobiotics NV | Treatment of immune disease by mucosal delivery of antigens |
| US20110044945A1 (en) * | 2007-02-08 | 2011-02-24 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of multiple sclerosis and methods of using same |
| WO2008155120A2 (en) | 2007-06-20 | 2008-12-24 | Actogenix Nv | Methods and compositions for treating mucositis |
| US8435953B2 (en) | 2007-11-07 | 2013-05-07 | Yasuhiko Tabata | Sustained release composition containing SDF-1 |
| WO2009079451A2 (en) | 2007-12-14 | 2009-06-25 | The Cleveland Clinic Foundation | Compositions and methods of promoting wound healing |
| US8367109B2 (en) | 2008-04-09 | 2013-02-05 | Brookhaven Science Associates, Llc | Microbes encapsulated within crosslinkable polymers |
| EP2344626B1 (en) | 2008-09-29 | 2017-03-29 | Intrexon Actobiotics NV | Reduced colonization of microbes at the mucosa |
| US20100143305A1 (en) * | 2008-12-08 | 2010-06-10 | James Allen Lemke | Treatment of hiv and aids using probiotic lactobacillus reuteri |
| WO2010123699A2 (en) | 2009-04-21 | 2010-10-28 | University Of Miami | Compositions, kits and methods for promoting ischemic and diabetic wound healing |
| EP2243487A1 (en) | 2009-04-23 | 2010-10-27 | Actogenix N.V. | Enteric coated formulation |
| WO2010124855A1 (en) | 2009-04-30 | 2010-11-04 | Actogenix Nv | Cryoprotectants for freeze drying of lactic acid bacteria |
| US20100310514A1 (en) * | 2009-06-04 | 2010-12-09 | Chi Hin Cho | Anti-Inflammatory Bacteria |
| CL2009001506A1 (es) | 2009-07-01 | 2009-09-25 | Univ Concepcion | Parche o aposito a base de hidrocoloides compuesto por una lamina de gelatina reticulada que comprende cepas viables probioticas productoras de acido lactico de lactobacillus acidophilus dsm 17371, un agente reticulante y un agente plastificante; y proceso para elaborar dicho parche. |
| US20120283315A1 (en) | 2009-08-28 | 2012-11-08 | Penn Marc S | Sdf-1 delivery for treating ischemic tissue |
| EP3192873A1 (en) | 2009-09-29 | 2017-07-19 | Intrexon Actobiotics NV | Lactobacillus and streptococcus promoters and uses thereof |
| GB2482536B (en) * | 2010-08-05 | 2013-07-24 | Hera Pharmaceuticals Inc | Expression of antibody or a fragment thereof in lactobacillus |
| CN101985052B (zh) | 2010-08-31 | 2013-11-06 | 中国人民解放军第二军医大学 | 自动捕获内皮祖细胞促进血管化的皮肤替代物及其构建方法 |
| DK2704704T3 (en) | 2011-05-03 | 2019-01-14 | Dupont Nutrition Biosci Aps | PROBIOTIC BACTERIES FOR TOPICAL TREATMENT OF SKIN DISORDERS |
| US9920324B2 (en) | 2011-06-01 | 2018-03-20 | Intrexon Actobiotics Nv | Polycistronic expression system for bacteria |
| EP2758512B1 (en) | 2011-09-23 | 2018-05-09 | Intrexon Actobiotics NV | Modified gram positive bacteria and uses thereof |
| BR112014006883A8 (pt) | 2011-09-23 | 2018-06-26 | Actogenix Nv | bactéria gram-positiva não patogênica carecendo de atividade do componente llc do sistema pts celobiose específico (ptcc), medicamento, aditivo alimentar, composição probiótica, ou cultura iniciadora, produto alimentar e métodos |
| GB201206599D0 (en) | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
| CN105263507A (zh) | 2013-03-15 | 2016-01-20 | 尤文塔斯医疗公司 | 使用sdf-1减轻瘢痕形成 |
| WO2014146202A1 (en) * | 2013-03-18 | 2014-09-25 | London Health Sciences Centre Research Inc. | Bacteria for the prevention, treatment and diagnosis of breast cancer |
| HUE059749T2 (hu) | 2013-04-29 | 2022-12-28 | Medregen Llc | Sebgyógyítás autológ õssejt-mobilizáció útján |
| WO2016124239A1 (en) | 2015-02-04 | 2016-08-11 | Aurealis Oy | Recombinant probiotic bacteria for use in the treatment of a skin dysfunction |
-
2015
- 2015-12-23 CA CA2971520A patent/CA2971520C/en active Active
- 2015-12-23 AU AU2015370982A patent/AU2015370982B2/en active Active
- 2015-12-23 EP EP20161504.4A patent/EP3735979B1/en active Active
- 2015-12-23 CN CN201580070791.8A patent/CN107208107B/zh active Active
- 2015-12-23 US US15/538,384 patent/US10696974B2/en active Active
- 2015-12-23 KR KR1020207004865A patent/KR102297619B1/ko active Active
- 2015-12-23 KR KR1020177020505A patent/KR102081493B1/ko active Active
- 2015-12-23 WO PCT/EP2015/081146 patent/WO2016102660A1/en not_active Ceased
- 2015-12-23 CN CN202110680754.6A patent/CN113403244B/zh active Active
- 2015-12-23 EP EP15822941.9A patent/EP3237622B1/en active Active
- 2015-12-23 ES ES20161504T patent/ES3048233T3/es active Active
- 2015-12-23 ES ES15822941T patent/ES2864373T3/es active Active
- 2015-12-23 JP JP2017552233A patent/JP6581208B2/ja active Active
-
2019
- 2019-06-19 AU AU2019204290A patent/AU2019204290B2/en active Active
- 2019-08-29 JP JP2019156412A patent/JP7033109B2/ja active Active
-
2020
- 2020-06-05 US US16/893,781 patent/US11473091B2/en active Active
-
2022
- 2022-08-11 US US17/819,274 patent/US20230093013A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502600A5 (enExample) | ||
| Papagianni | Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications | |
| JP6866974B2 (ja) | 新規なエンドリシンポリペプチド | |
| Mandal et al. | Recombinant probiotics with antimicrobial peptides: a dual strategy to improve immune response in immunocompromised patients | |
| JP2021501581A5 (enExample) | ||
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| HRP20241279T1 (hr) | Pripravak koji sadrži probiotike koji prekomjerno eksprimiraju protein clpb za uporabu u liječenju pretilosti | |
| RU2017142932A (ru) | Фармацевтические и пищевые композиции для индуцирования насыщения и продления сытости у нуждающихся в этом субъектов | |
| WO2017084985A1 (en) | Bacteriocin composition and method | |
| Sivaraj et al. | Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy | |
| JP2019505567A5 (enExample) | ||
| MX2023015156A (es) | Peptidos antimicrobianos modificados. | |
| JP2013542942A5 (enExample) | ||
| Silpa et al. | Cyclic peptide production from lactic acid bacteria (LAB) and their diverse applications | |
| ES2808780T3 (es) | Nuevos péptidos antimicrobianos, sus variantes y usos | |
| Niu et al. | Full‐length cDNA, prokaryotic expression, and antimicrobial activity of UuHb‐F‐I from Urechis unicinctus | |
| O’Sullivan et al. | Nisin variants from Streptococcus and Staphylococcus successfully express in NZ9800 | |
| IL297430A (en) | Chimeric endolysin polypeptide | |
| WO2019059817A9 (en) | VACCINE BASED ON FUSION PROTEIN AND PLASMIDIC DNA | |
| CN106749534B (zh) | 一种许氏平鮋抗菌肽bs20及其应用 | |
| US11648289B2 (en) | Antibacterial method | |
| WO2019033007A3 (en) | Staphylococcus pseudintermedius virulence factor compositions | |
| KR102311729B1 (ko) | 유산균에서 분리한 항균 펩타이드 플랜타리신 및 이의 용도 | |
| MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. |